Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors

Por Szakács, Dávid, Kocsis, Andrea, Szász, Róbert, Gál, Péter, Pál, Gábor
Publicado no J Biol Chem (2019)

Ibrutinib-induced acute kidney injury via interstitial nephritis

Por Markóth, Csilla, File, Ibolya, Szász, Róbert, Bidiga, László, Balla, József, Mátyus, János
Publicado no Ren Fail (2021)

Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia

Por Tolnai, Emese, Fidler, Gábor, Szász, Róbert, Rejtő, László, Nwozor, Kingsley Okechukwu, Biró, Sándor, Paholcsek, Melinda
Publicado no Sci Rep (2020)

Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2

Por Héja, Dávid, Kocsis, Andrea, Dobó, József, Szilágyi, Katalin, Szász, Róbert, Závodszky, Péter, Pál, Gábor, Gál, Péter
Publicado em 2012

MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked

Por Dobó, József, Szakács, Dávid, Oroszlán, Gábor, Kortvely, Elod, Kiss, Bence, Boros, Eszter, Szász, Róbert, Závodszky, Péter, Gál, Péter, Pál, Gábor
Publicado no Sci Rep (2016)

Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from...

Por Szász, Róbert, Altai, Elvira, Pál, Katalin, Dombi, Péter, Iványi, János, Jakucs, János, Jóni, Natália, Illés, Árpád, Tárkányi, Ilona, Szerafin, László, Nagy, Zsolt, Farkas, Péter, Nagy, Ágnes, Piukovics, Klára, Ujj, György, Schneider, Tamás
Publicado no Pathol Oncol Res (2018)